| Identification | Back Directory | [Name]
4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- | [CAS]
2360851-29-0 | [Synonyms]
RBN012759
4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- | [Molecular Formula]
C19H23FN2O3S | [MDL Number]
MFCD32857169 | [MOL File]
2360851-29-0.mol | [Molecular Weight]
378.46 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 250 mg/mL (660.57 mM; Need ultrasonic) | [form ]
A solid | [color ]
White to off-white | [InChI]
InChI=1S/C19H23FN2O3S/c20-15-7-13(25-9-11-1-2-11)8-16-18(15)19(24)22-17(21-16)10-26-14-5-3-12(23)4-6-14/h7-8,11-12,14,23H,1-6,9-10H2,(H,21,22,24)/t12-,14- | [InChIKey]
NKZDEFKPZSLQRF-MQMHXKEQSA-N | [SMILES]
N1C2=C(C(F)=CC(OCC3CC3)=C2)C(=O)NC=1CS[C@@H]1CC[C@@H](O)CC1 |
| Hazard Information | Back Directory | [Uses]
RBN012759 is an inhibitor of PARP14, which is useful in the treatment of cancer and inflammatory diseases. | [in vivo]
RBN012759 (500 mg/kg BID; p.o.) is well-tolerated in mice with repeat dosing[1].
?
RBN012759 (100 mg/kg; p.o.) exhibits moderate orally bioavailability (30%) and short plasma half-life (0.4 h) due to moderate clearance (54 mL/min/kg) and low steady-state volume of distribution (1.4 L/kg) in mice[1]. | [IC 50]
PARP14: <3 nM (IC50); PARP4: 10 μM (IC50); PARP5a: 8 μM (IC50); PARP5b: 10 μM (IC50); PARP6: 4 μM (IC50); PARP7: 4 μM (IC50); PARP8: 20 μM (IC50); PARP10: 1 μM (IC50); PARP11: 1 μM (IC50); PARP12: 5 μM (IC50); PARP15: 3 μM (IC50); PARP16: 6 μM (IC50) | [storage]
4°C, protect from light |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|